Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ponesimod
Drug ID BADD_D02584
Description Ponesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults.[A232079,L32709] Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-phosphate receptor 1 than [fingolimod].[A232079] Fingolimod's activity at sphingosine 1-phosphate receptor 3 was suspected to be responsible for a portion of it's adverse effects, and so more selective modulators were developed.[A232079] Ponesimod was granted FDA approval on 18 March 2021.[L32709]
Indications and Usage Ponesimod is indicated to treat adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.[L32709]
Marketing Status approved; investigational
ATC Code L04AA50
DrugBank ID DB12016
KEGG ID D11215
MeSH ID C550169
PubChem ID Not Available
TTD Drug ID D0Y4SI
NDC Product Code 50458-707; 50458-720
UNII 5G7AKV2MKP
Synonyms ponesimod | 5-(3-chloro-4-(2,3-dihydroxy-propoxy)benzylidene)-2-propylimino-3-o-tolyl-thiazolidin-4-one | ponvory | ACT 128800 | ACT128800 | ACT-128800
Chemical Information
Molecular Formula Not Available
CAS Registry Number 854107-55-4
SMILES Not Available
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Therapy non-responder08.06.01.0630.000820%Not Available
The 2th Page    First    Pre   2    Total 2 Pages